Healthcare provider profile · identity verified

Denise Nguyen, MD

Family Practice · ELK GROVE, CA · NPI 1689722613

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	600	217
Losartan Potassium	Losartan Potassium	405	136
Amlodipine Besylate	Amlodipine Besylate	365	133
Fluticasone Propionate	Fluticasone Propionate	230	108
Levothyroxine Sodium	Levothyroxine Sodium	222	84
Famotidine	Famotidine	199	88
Lisinopril	Lisinopril	178	69
Alendronate Sodium	Alendronate Sodium	166	64
Gabapentin	Gabapentin	166	62
Omeprazole	Omeprazole	123	66
Metformin Hcl	Metformin Hcl	114	45
Tamsulosin Hcl	Tamsulosin Hcl	100	39
Hydrochlorothiazide	Hydrochlorothiazide	98	33
Metformin Hcl Er	Metformin Hcl	93	41
Simvastatin	Simvastatin	93	33
Albuterol Sulfate Hfa	Albuterol Sulfate	90	62
Triamcinolone Acetonide	Triamcinolone Acetonide	84	53
Metoprolol Tartrate	Metoprolol Tartrate	71	29
Metoprolol Succinate	Metoprolol Succinate	67	24
Duloxetine Hcl	Duloxetine Hcl	61	30
Allopurinol	Allopurinol	60	28
Ibuprofen	Ibuprofen	57	26
Montelukast Sodium	Montelukast Sodium	57	23
Hydrocortisone	Hydrocortisone	53	21
Meloxicam	Meloxicam	53	24
Pantoprazole Sodium	Pantoprazole Sodium	51	28
Atenolol	Atenolol	48	19
Furosemide	Furosemide	47	21
Carvedilol	Carvedilol	46	19
Alvesco	Ciclesonide	42	22
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	42	14
Glipizide	Glipizide	41	19
Potassium Chloride	Potassium Chloride	40	17
Rosuvastatin Calcium	Rosuvastatin Calcium	37	16
Finasteride	Finasteride	35	13
Sertraline Hcl	Sertraline Hcl	35	14
Trazodone Hcl	Trazodone Hcl	34	19
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	33	13
Ondansetron Hcl	Ondansetron Hcl	33	suppressed
Fluocinonide	Fluocinonide	32	13
Hydralazine Hcl	Hydralazine Hcl	31	14
Baclofen	Baclofen	30	15
Pravastatin Sodium	Pravastatin Sodium	29	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	28	suppressed
Spiriva Respimat	Tiotropium Bromide	27	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	26	26
Wixela Inhub	Fluticasone Propion/Salmeterol	25	suppressed
Cromolyn Sodium	Cromolyn Sodium	24	16
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	24	suppressed
Glipizide Er	Glipizide	23	11
Hydroxyzine Hcl	Hydroxyzine Hcl	23	15
Cefadroxil	Cefadroxil	22	21
Eliquis	Apixaban	22	suppressed
Lidocaine	Lidocaine	22	12
Clopidogrel	Clopidogrel Bisulfate	20	suppressed
Lovastatin	Lovastatin	20	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	19	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Jardiance	Empagliflozin	17	suppressed
Fluoxetine Hcl	Fluoxetine Hcl	16	suppressed
Glimepiride	Glimepiride	16	suppressed
Acyclovir	Acyclovir	15	suppressed
Meclizine Hcl	Meclizine Hcl	15	suppressed
Mirtazapine	Mirtazapine	15	suppressed
Pradaxa	Dabigatran Etexilate Mesylate	15	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	15	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	14	14
Breyna	Budesonide/Formoterol Fumarate	14	suppressed
Nitroglycerin	Nitroglycerin	14	suppressed
Citalopram Hbr	Citalopram Hydrobromide	13	suppressed
Doxycycline Monohydrate	Doxycycline Monohydrate	12	11
Insulin Glargine-Yfgn	Insulin Glargine-Yfgn	12	suppressed
Nifedipine Er	Nifedipine	12	suppressed
Raloxifene Hcl	Raloxifene Hcl	12	suppressed
Rizatriptan	Rizatriptan Benzoate	12	suppressed
Sucralfate	Sucralfate	12	suppressed
Ultra-Fine Mini Pen Needle	Pen Needle, Diabetic	12	suppressed
Bisoprolol Fumarate	Bisoprolol Fumarate	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Pregabalin	Pregabalin	11	suppressed
Propranolol Hcl	Propranolol Hcl	11	suppressed
Ropinirole Hcl	Ropinirole Hcl	11	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error